Clinical analysis of 48 cases of malignant superior vena cava syndrome

World Journal of Surgical Oncology

Xiaofei Wang¹  Xudong Zhang¹  Lin Wang¹  Guowen Li¹  Hongfei Li¹  Ruipan Zheng¹  Dianyuan Li²  Xiaoli Chen²  Manzhen Sun² 

[1] Radiotherapy Inpatient Ward II, The First Affiliated Hospital of Zhengzhou University, No. 1 Eastern Jianshe Road, 450052, Zhengzhou, Henan Province, China;School of Basic Medical Sciences, Zhengzhou University, No. 100 Science Avenue, 450000, Zhengzhou, Henan Province, China;

关键词: Superior vena cava syndrome;    Malignant etiology;    Radiotherapy;    Chemotherapy;    Comprehensive treatment;   

DOI  :  10.1186/s12957-021-02300-8

来源: Springer

【 摘 要 】

BackgroundThe aim of our study was to observe and compare the curative effect of radiotherapy, chemotherapy, and combined radiotherapy and chemotherapy, as well as comprehensive treatment on superior vena cava syndrome (SVCS) caused by malignant etiology.MethodsA total of 48 patients with malignant SVCS admitted to our hospital from 2015 to 2020 were selected in this study. According to the different treatment methods, they were divided into radiotherapy group (group 1, 10 cases), chemotherapy group (group 2, 8 cases), combined radiotherapy and chemotherapy group (group 3, 22 cases), and comprehensive treatment group (group 4, 8 cases).ResultsThere were no significant differences in efficacy and side effects among the four groups (all P > 0.05). Group 4 (median survival time of 36 months) could provide longer survival time than groups 1, 2, and 3 (median survival time of 10 months, 13.5 months, and 12 months, respectively).ConclusionsFor patients with severe symptoms or good prognosis, comprehensive treatment could be selected to improve the quality of life and prolong the survival period; for patients with mild symptoms, radiotherapy, chemotherapy, or combined radiotherapy and chemotherapy could also reduce the symptoms of SVCS and treat tumor lesions.

【 授权许可】

CC BY